Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results

Press Release:


Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results

Long-Acting VRS-317 Efficacy and Safety Comparable to Daily Growth Hormone Therapies

Company to Hold Conference Call at 5:00 p.m. EDT (4:00 p.m. CDT)

CHICAGO, June 23, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today presented positive Phase 2a data from its six month clinical trial demonstrating the safety and efficacy of VRS-317 in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD). These results are being presented by George Bright, MD, Versartis Vice President of Clinical Development, during the clinical poster session, "Growth and GH: Diagnostic Issues and Treatment" from 1:00 - 3:00 p.m. CDT today at the 16th International Congress of Endocrinology and The Endocrine Society's 96th Annual Meeting and Expo (ICE/ENDO 2014) in Chicago, IL.

The full press release is available on Advent Life Sciences website.

Back